| Project/Area Number |
20390384
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (B)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Cerebral neurosurgery
|
|---|
| Research Institution | Hyogo College of Medicine |
|---|
Principal Investigator |
IZUMOTO Shuichi Hyogo College of Medicine, 医学部, 准教授 (40324769)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
TSUBOI Akihiro 大阪大学, 医学系研究科, 寄附講座准教授 (10372608)
HASHIMOTO Naoya 大阪大学, 医学系研究科, 准教授 (90315945)
KINOSHITA Manabu 大阪大学, 医学系研究科, 助教 (40448064)
MORI Kanji 兵庫医科大学, 医学部, 講師 (50360269)
YUSUKE Tomogane 兵庫医科大学, 医学部, 助教 (10412008)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥16,640,000 (Direct Cost: ¥12,800,000、Indirect Cost: ¥3,840,000)
Fiscal Year 2010: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2009: ¥5,850,000 (Direct Cost: ¥4,500,000、Indirect Cost: ¥1,350,000)
Fiscal Year 2008: ¥7,670,000 (Direct Cost: ¥5,900,000、Indirect Cost: ¥1,770,000)
|
|---|
| Keywords | 悪性神経膠腫 / 膠芽腫 / WT1 / 免疫療法 / がんワクチン療法 / 悪性グリオーマ |
|---|
| Research Abstract |
The safety and clinical responses of immunotherapy targeting the WT1 combined with chemotherapy against the patients with newly diagnosed malignant glioma were investigated. (1) The frequency of WT1-specific cytotoxic T lymphocytes in blood was increased from 0.196% to 0.256% during the combined treatment of TMZ/RT for 6 weeks. The frequency of Treg cells was increased from 4.8% to 7.5% during the combined treatment of TMZ/RT for 6 weeks, but the cell count was not changed. (2) "Phase I clinical trial of WT1 immunotherapy combined with temozolomide chemotherapy against the patients with newly diagnosed malignant glioma" was performed and was safe. (3) Expression of IFN-γand IL-10 from WT1-specific CD4+ helper T cells were investigated by RT-PCR. In patients who responded, a clear inverse correlation between IL-10-type and IFN-gamma-type WT1(332)-specific Th response was detected at pre- and 4 weeks post-vaccination. (4) Based on these results, WT1 immunotherapy combined with TMZ chemotherapy was safe and produced a immune-response.
|
